Table 2.

Completed or ongoing analyses from randomized, placebo-controlled studies with pimavanserin for neuropsychiatric disorders

Reference	Study Population	Treatments	Primary Endpoint	Primary Outcome
ACP-103-020 (29)	Parkinson’s disease psychosis	Pimavanserin 34 mg vs. placebo	SAPS-PD change from baseline to Week 6	Significant improvement with pimavanserin vs. placebo
ACP-103-020 (46)	Parkinson’s disease psychosis	Pimavanserin 34 mg vs. placebo	SAPS-PD at Week 6 stratified by baseline MMSE	Significant improvement in both groups, but more robust in cognitively impaired
ACP-103-019 (30)	Alzheimer’s disease psychosis	Pimavanserin 34 mg vs. placebo	NPI-NH psychosis at Week 6	Significant improvement for pimavanserin vs. placebo
ACP-103-019 (47)	Alzheimer’s disease psychosis	Pimavanserin 34 mg vs. placebo	NPI-NH psychosis score at Week 6 by severity	Significant and more robust response in the severe subgroup
NCT03325556 [ACP-103-045]	Dementia-related psychosis	Pimavanserin (20 mg and 34 mg flexible dosing) vs. placebo	Time from randomization to relapse; Time from randomization to all-cause discontinuation	Ongoing